Bupivacaine inhibited tumor cell proliferation and migration through AKT/mTOR signaling pathway to increase the expression of Beclin-1 and the expression ratio of light chain 3B-II (LC3B-II)/LC3B-I in NSCLC cells (Gu et al., 2021). The gene discussed is AKT1; the disease is non-small cell lung carcinoma.